oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2026-25-4-110-115oncotomsk-4417Research ArticleОПЫТ РАБОТЫ ОНКОЛОГИЧЕСКИХ УЧРЕЖДЕНИЙONCOLOGY PRACTICEВлияние лучевой терапии на гематологические клетки у онкологических пациентов в развивающейся странеImpact of radiation therapy on hematological cells among cancer patients in a developing countryhttps://orcid.org/0000-0002-6238-1705MajeedImranMajeedImran

MD, PhD, врач-консультант по радиационной онкологии, Больница Джинна.

Лахор

MD, PhD, Consultant Physicist, Radiation Oncology, Jinnah Hospital.

Lahore

bisimran@gmail.comFarooqMehreenFarooqMehreen

MD, MBBS, MCPS, радиационная онкология, Больница Джинна.

Лахор

MD, MBBS, MCPS, Radiation Oncology, Jinnah Hospital.

Lahore

AliCapt MubashirAliCapt Mubashir

MD, MBBS DMRT, радиотерапевт, Больница Джинна.

Лахор

MD, MBBS DMRT, Consultant Radiation Oncology, Jinnah Hospital.

Lahore

HussainMazharHussainMazhar

MD, MBBS FCPS, радиотерапевт, Больница Джинна.

Лахор

MD, MBBS FCPS, Consultant Radiation Oncologist, Jinnah Hospital.

Lahore

ZebMaryamZebMaryam

MD, MBBS, отделение лучевой терапии, Больница Джинна.

Лахор

MD, MBBS, Radiation Oncology, Jinnah Hospital.

Lahore

NazirAbeehaNazirAbeeha

MPhil, Лахорский технологический университет.

Лахор

MPhil, University of Engineering and Technology.

Lahore

AmjadFatimaAmjadFatima

MD, MBBS, Больница Джинна.

Лахор

MD, MBBS, Jinnah Hospital.

Lahore

HameedKashifHameedKashif

MD, MBBS, Отделение лучевой терапии, Больница Джинна.

Лахор

MD, MBBS, Radiation Oncology, Jinnah Hospital.

Lahore

Больница ДжиннаПакистанJinnah HospitalPakistan202621092026254110115Copyright © Majeed I., Farooq M., Ali C.M., Hussain M., Zeb M., Nazir A., Amjad F., Hameed K., 20262026Majeed I., Farooq M., Ali C.M., Hussain M., Zeb M., Nazir A., Amjad F., Hameed K.Majeed I., Farooq M., Ali C.M., Hussain M., Zeb M., Nazir A., Amjad F., Hameed K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/4417

Введение. Иммунная система – сложная сеть органов, клеток и белков. Здоровая иммунная система способна распознать и уничтожить болезнетворные микроорганизмы (или патогены), а также раковые клетки, защищая при этом здоровые ткани. Лейкоциты являются ключевым звеном иммунной системы. Цель исследования – оценка влияния лучевой терапии на иммунную систему. Материал и методы. Данные 106 онкологических пациентов были собраны в отделении радиационной онкологии больницы Джинна в Лахоре, Пакистан, в период с января 2018 г. по сентябрь 2022 г. У пациентов проводился общий анализ крови до и после терапии. Результаты. Среди пациентов было 54,2 % женщин и 45,7 % мужчин в возрасте от 29 до 80 лет. У 64 % пациентов наблюдалось снижение количества тромбоцитов, у 71,4 % – снижение уровня гемоглобина, у 68,5 % – снижение общего количества лейкоцитов после лучевой терапии. Заключение. На основании анализа полученных данных установлено, что лучевая терапия влияет на иммунную систему пациентов. У большинства пациентов после лечения наблюдалось снижение уровня гемоглобина, количества лейкоцитов и тромбоцитов.

Background. Immune system is made up of different organs, cells and proteins. a healthy immune system can defeat invading disease-causing germs (or pathogens), such as bacteria, viruses, parasites as well as cancer cells while protecting healthy tissue. White blood cells are the key players in the hematological immune system. Objective. The aim of this research is to detect the radiation therapy effect on the immune system. Material and Methods. Data of 106 cancer patients have been collected from Department of Radiation Oncology, Jinnah Hospital Lahore, Pakistan since January 2018 to September 2022 and compete blood count of these patients is seen regularly before and after therapy. Results. There were 54.2 % female and 45.7 % male patients in the age range of 29–80 years. The 64 % patients were observed with decrease in platelets count, 71.4 % cancer patients had shown a reduction in hemoglobin level and 68.5 % of patients indicated a decline in TLC after the radiation therapy. Conclusion. Conclusions have been drawn from analyzing the data in this research work. Radiation therapy affects the immune system of the patients. Majority of patients have low White Blood Cells Counts after the treatment and also showed low Hemoglobin and Platelets Count.

лучевая терапиягематологические нарушенияиммунная системавоспалениеionizing radiationhematological immune systeminflammationReferencesVaiserman A., Koliada A., Zabuga O., Socol Y. Health Impacts of Low-Dose Ionizing Radiation: Current Scientific Debates and Regulatory Issues. Dose Response. 2018; 16(3): 1559325818796331. doi: 10.1177/1559325818796331.Vaiserman A., Koliada A., Zabuga O., Socol Y. Health Impacts of Low-Dose Ionizing Radiation: Current Scientific Debates and Regulatory Issues. Dose Response. 2018; 16(3): 1559325818796331. doi: 10.1177/1559325818796331.Brundha M.P., Pathmashri V.P., Sundari S. Quantitative changes of red blood cells in cancer patients under palliative radiotherapy – A retrospective study. Res J Pharm Technol. 2019; 12(2): 687–92. doi: 10.5958/0974-360X.2019.00122.7.Brundha M.P., Pathmashri V.P., Sundari S. Quantitative changes of red blood cells in cancer patients under palliative radiotherapy – A retrospective study. Res J Pharm Technol. 2019; 12(2): 687–92. doi: 10.5958/0974-360X.2019.00122.7.Chen H.H.W., Kuo M.T. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 2017; 8(37): 62742–58. doi: 10.18632/oncotarget.18409.Chen H.H.W., Kuo M.T. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 2017; 8(37): 62742–58. doi: 10.18632/oncotarget.18409.De Ruysscher D., Niedermann G., Burnet N.G., Siva S., Lee A.W.M., Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019; 5(1): 13. doi: 10.1038/s41572-019-0064-5. Erratum in: Nat Rev Dis Primers. 2019; 5(1): 15. doi: 10.1038/s41572-019-0073-4.De Ruysscher D., Niedermann G., Burnet N.G., Siva S., Lee A.W.M., Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019; 5(1): 13. doi: 10.1038/s41572-019-0064-5. Erratum in: Nat Rev Dis Primers. 2019; 5(1): 15. doi: 10.1038/s41572-019-0073-4.Alet A.I., Porini S., Riquelme B.D., Bisio A., Scifoni E., Galassi M.E. Effects of ionizing radiations of different qualities and delivery types on blood cells. Biophys Rev. 2025; 17(2): 579–90. doi: 10.1007/s12551-025-01302-0.Alet A.I., Porini S., Riquelme B.D., Bisio A., Scifoni E., Galassi M.E. Effects of ionizing radiations of different qualities and delivery types on blood cells. Biophys Rev. 2025; 17(2): 579–90. doi: 10.1007/s12551-025-01302-0.Jameus A., Kennedy A.E., Thome C. Hematological Changes Following Low Dose Radiation Therapy and Comparison to Current Standard of Care Cancer Treatments. Dose Response. 2021; 19(4): 15593258211056196. doi: 10.1177/15593258211056196.Jameus A., Kennedy A.E., Thome C. Hematological Changes Following Low Dose Radiation Therapy and Comparison to Current Standard of Care Cancer Treatments. Dose Response. 2021; 19(4): 15593258211056196. doi: 10.1177/15593258211056196.El-Dessouky Y.M., El-Dessouky M.M., El-Batrawy O.A. Penicillamine as radiation protector against gamma radiation effect on complete blood count parameters of guinea pigs.AlAzharAssiut Med J. 2019; 17(2): 145–53. doi: 10.4103/AZMJ.AZMJ_137_18.El-Dessouky Y.M., El-Dessouky M.M., El-Batrawy O.A. Penicillamine as radiation protector against gamma radiation effect on complete blood count parameters of guinea pigs.AlAzharAssiut Med J. 2019; 17(2): 145–53. doi: 10.4103/AZMJ.AZMJ_137_18.Wisdom A.J., Barker C.A., Chang J.Y., Demaria S., Formenti S., Grassberger C., Gregucci F., Hoppe B.S., Kirsch D.G., Marciscano A.E., Mayadev J., Mouw K.W., Palta M., Wu C.C., Jabbour S.K., Schoenfeld J.D. The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives. Int J Radiat Oncol Biol Phys. 2024; 118(5): 1404–21. doi: 10.1016/j.ijrobp.2023.12.046.Wisdom A.J., Barker C.A., Chang J.Y., Demaria S., Formenti S., Grassberger C., Gregucci F., Hoppe B.S., Kirsch D.G., Marciscano A.E., Mayadev J., Mouw K.W., Palta M., Wu C.C., Jabbour S.K., Schoenfeld J.D. The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives. Int J Radiat Oncol Biol Phys. 2024; 118(5): 1404–21. doi: 10.1016/j.ijrobp.2023.12.046.Abdul-Latif M., Conibear J., Thiruthaneeswaran N., Tsang Y.M. Does radiation-induced lymphocytopenia matter? Developing a radiotherapy dosimetric strategy for immune preservation and improved survival. BMJ Oncol. 2025; 4(1): e000745. doi: 10.1136/bmjonc-2025-000745.Abdul-Latif M., Conibear J., Thiruthaneeswaran N., Tsang Y.M. Does radiation-induced lymphocytopenia matter? Developing a radiotherapy dosimetric strategy for immune preservation and improved survival. BMJ Oncol. 2025; 4(1): e000745. doi: 10.1136/bmjonc-2025-000745.Chow J.C.H., Ho J.C.S., Cheung K.M., Johnson D., Ip B.Y.M., Beitler J.J., Strojan P., Mäkitie A.A., Eisbruch A., Ng S.P., Nuyts S., Mendenhall W.M., Babighian S., Ferlito A. Neurological complications of modern radiotherapy for head and neck cancer. Radiother Oncol. 2024; 194: 110200. doi: 10.1016/j.radonc.2024.110200.Chow J.C.H., Ho J.C.S., Cheung K.M., Johnson D., Ip B.Y.M., Beitler J.J., Strojan P., Mäkitie A.A., Eisbruch A., Ng S.P., Nuyts S., Mendenhall W.M., Babighian S., Ferlito A. Neurological complications of modern radiotherapy for head and neck cancer. Radiother Oncol. 2024; 194: 110200. doi: 10.1016/j.radonc.2024.110200.Jelonek K., Pietrowska M., Widlak P. Systemic effects of ion- izing radiation at the proteome and metabolome levels in the blood of cancer patients treated with radiotherapy: the influence of inflamma- tion and radiation toxicity. Int J Radiat Biol. 2017; 93(7): 683–96. doi: 10.1080/09553002.2017.1304590.Jelonek K., Pietrowska M., Widlak P. Systemic effects of ion- izing radiation at the proteome and metabolome levels in the blood of cancer patients treated with radiotherapy: the influence of inflamma- tion and radiation toxicity. Int J Radiat Biol. 2017; 93(7): 683–96. doi: 10.1080/09553002.2017.1304590.Swanson G.P., Hammonds K., Jhavar S. Reference Results for Blood Parameter Changes and Recovery after Pelvic Radiation without Chemotherapy. Hematol Rep. 2022; 14(2): 155–64. doi: 10.3390/hematolrep14020023.Swanson G.P., Hammonds K., Jhavar S. Reference Results for Blood Parameter Changes and Recovery after Pelvic Radiation without Chemotherapy. Hematol Rep. 2022; 14(2): 155–64. doi: 10.3390/hematolrep14020023.Wersal C., Keller A., Weiss C., Giordano F.A., Abo-Madyan Y., Tuschy B., Sütterlin M., Wenz F., Sperk E. Long-term changes in blood counts after intraoperative radiotherapy for breast cancer-single center experience and review of the literature. Transl Cancer Res. 2019; 8(5): 1882–903. doi: 10.21037/tcr.2019.09.05.Wersal C., Keller A., Weiss C., Giordano F.A., Abo-Madyan Y., Tuschy B., Sütterlin M., Wenz F., Sperk E. Long-term changes in blood counts after intraoperative radiotherapy for breast cancer-single center experience and review of the literature. Transl Cancer Res. 2019; 8(5): 1882–903. doi: 10.21037/tcr.2019.09.05.Joseph N., Cicchetti A., McWilliam A., Webb A., Seibold P., Fiorino C., Cozzarini C., Veldeman L., Bultijnck R., Fonteyne V., Talbot C.J., Symonds P.R., Johnson K., Rattay T., Lambrecht M., Haustermans K., De Meerleer G., Elliott R.M., Sperk E., Herskind C., Veldwijk M., Avuzzi B., Giandini T., Valdagni R., Azria D., Jacquet M.F., Charissoux M., Vega A., Aguado-Barrera M.E., Gómez-Caamaño A., Franco P., Garibaldi E., Girelli G., Iotti C., Vavassori V., Chang-Claude J., West C.M.L., Rancati T., Choudhury A. High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer. Front Oncol. 2022; 12: 937934. doi: 10.3389/fonc.2022.937934.Joseph N., Cicchetti A., McWilliam A., Webb A., Seibold P., Fiorino C., Cozzarini C., Veldeman L., Bultijnck R., Fonteyne V., Talbot C.J., Symonds P.R., Johnson K., Rattay T., Lambrecht M., Haustermans K., De Meerleer G., Elliott R.M., Sperk E., Herskind C., Veldwijk M., Avuzzi B., Giandini T., Valdagni R., Azria D., Jacquet M.F., Charissoux M., Vega A., Aguado-Barrera M.E., Gómez-Caamaño A., Franco P., Garibaldi E., Girelli G., Iotti C., Vavassori V., Chang-Claude J., West C.M.L., Rancati T., Choudhury A. High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer. Front Oncol. 2022; 12: 937934. doi: 10.3389/fonc.2022.937934.Yang Y., Hou X., Kong S., Zha Z., Huang M., Li C., Li N., Ge F., Chen W. Intraoperative radiotherapy in breast cancer: Alterations to the tumor microenvironment and subsequent biological outcomes (Review). Mol Med Rep. 2023; 28(6): 231. doi: 10.3892/mmr.2023.13118.Yang Y., Hou X., Kong S., Zha Z., Huang M., Li C., Li N., Ge F., Chen W. Intraoperative radiotherapy in breast cancer: Alterations to the tumor microenvironment and subsequent biological outcomes (Review). Mol Med Rep. 2023; 28(6): 231. doi: 10.3892/mmr.2023.13118.Joseph N., Alagiyawanna L., Ruwanpura T., Gunasekera S., Ruvinda L., Madushan S., Choudhury A. Whole-body integral dose and post-radiotherapy lymphocytopaenia in solid tumours. BMJ Oncol. 2025; 4(1): e000522. doi: 10.1136/bmjonc-2024-000522.Joseph N., Alagiyawanna L., Ruwanpura T., Gunasekera S., Ruvinda L., Madushan S., Choudhury A. Whole-body integral dose and post-radiotherapy lymphocytopaenia in solid tumours. BMJ Oncol. 2025; 4(1): e000522. doi: 10.1136/bmjonc-2024-000522.Terrones-Campos C., Ledergerber B., Vogelius I.R., Helleberg M., Specht L., Lundgren J. Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival. Radiother Oncol. 2021; 158: 175–83. doi: 10.1016/j.radonc.2021.02.029.Terrones-Campos C., Ledergerber B., Vogelius I.R., Helleberg M., Specht L., Lundgren J. Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival. Radiother Oncol. 2021; 158: 175–83. doi: 10.1016/j.radonc.2021.02.029.

The authors declare that there are no conflicts of interest present.